43% overturnedAppeal outcomes · Oncology

Denied proton beam therapy: what independent reviewers actually decided

Proton therapy is denied as investigational or as no better than photons more than almost anything else in the corpus — and the appeals that won did not argue superiority in general.

Charged-particle radiotherapy delivered in place of conventional photon radiation, billed with its own delivery and management codes. Plans route it through oncology benefit criteria that enumerate accepted indications narrowly.

What the independent reviewers decided

43%

overturned by the independent reviewer

96

of 226 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny proton beam therapy

  • The policy lists proton therapy as medically necessary only for enumerated tumour types and the requested indication is outside them.
  • The plan holds that photon radiotherapy is equally effective and therefore the proton course is not necessary.
  • The submitted plan does not include a comparative dosimetric analysis the policy expects.
  • The indication is treated as investigational because the policy relies on evidence reviews that predate the current literature.

What actually carried the cases that won

Severity and red-flag findings dominated the overturned decisions here — the risk to a specific organ at risk, the proximity of the target, the patient's age or prior irradiation. The successful pattern is not a general claim that protons are better; it is a documented, patient-specific reason that the dose to normal tissue matters in this case. Clinical guidelines and specialty-society criteria were the authorities reviewers cited most.

What the record showedShare of overturned decisions
The severity or urgency was documented99%
Objective findings were documented56%
A published guideline supported the request39%
The functional impact on the patient was documented32%
The condition was documented as chronic or long-standing20%
The diagnosis was confirmed7%
Conservative treatment was documented as failed3%
Prior treatment was documented1%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

  • Clinical guidelines — in 52% of the overturned decisions
  • Specialty-society criteria — in 47% of the overturned decisions
  • Peer-reviewed literature — in 35% of the overturned decisions
  • Standard of care — in 2% of the overturned decisions

proton beam therapy denials — frequently asked

Is a denied proton therapy claim worth appealing?
43% of 226 California independent medical reviews were overturned — a minority, and one of the lower rates in this corpus. That is worth knowing before spending the effort, and it is also why the argument matters more here than almost anywhere else.
What did the successful appeals argue?
Patient-specific risk, not modality superiority. The overturned records tended to identify the organ at risk, the reason conventional planning could not spare it adequately, and what that means for this patient — prior radiation, young age, a target adjacent to critical structures.
Does a comparative dosimetric plan help?
Where the policy asks for one, its absence is a clean procedural reason to deny. Submitting it converts the dispute from whether protons are generally warranted into whether this plan spares tissue that the photon plan does not, which is the ground the overturned cases were decided on.

Related guides

How external review worksCO-50 — not medically necessaryOncology denials

Source

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →